Claire Le Jeunne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Claire Le Jeunne has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Anne Carpentier
Les entreprises du médicaments (LEEM), Paris, France
2 shared publicationsAnne Dandon
Haute Autorité de Santé, Saint-Denis la Plaine, France
2 shared publicationsChristine Vernotte
Laboratoire Lilly France, Suresnes, France
2 shared publicationsDanièle Girault
Laboratoire Novartis Pharma, Rueil-Malmaison, France
2 shared publicationsDriss Berdaï
Centre hospitalier de Bordeaux, Bordeaux, France
2 shared publicationsEmmanuelle Cohn
Haute Autorité de Santé, Saint-Denis la Plaine, France
2 shared publications
Latest Publications
- Open Access
- 24 November 2014
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 16 (6) , 487
Neurotrophins are expressed in giant cell arteritis lesions and may contribute to vascular remodeling
Introduction: Giant cell arteritis (GCA) is characterized by intimal hyperplasia leading to ischaemic manifestations that involve large vessels. Neurotrophins (NTs) and their receptors (NTRs) are protein factors for growth, differentiation and survival of neurons. They are also involved in the migration of vascular smooth muscle cells (VSMCs). Our aim was to investigate whether NTs and NTRs are involved in vascular remodelling of GCA. Methods: We included consecutive patients who underwent a temporal artery biopsy for suspected GCA. We developed an enzymatic digestion method to obtain VSMCs from smooth muscle cells in GCA patients and controls. Neurotrophin protein and gene expression and functional assays were studied from these VSMCs. Neurotrophin expression was also analysed by immunohistochemistry in GCA patients and controls. Results: Whereas temporal arteries of both GCA patients (n = 22) and controls (n = 21) expressed nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), tropomyosin receptor kinase B (TrkB) and sortilin, immunostaining was more intense in GCA patients, especially in the media and intima, while neurotrophin-3 (NT-3) and P75 receptor (P75NTR) were only detected in TA from GCA patients. Expression of TrkB, a BDNF receptor, was higher in GCA patients with ischaemic complications. Serum NGF was significantly higher in GCA patients (n = 28) vs. controls (n = 48), whereas no significant difference was found for BDNF and NT-3. NGF and BDNF enhanced GCA-derived temporal artery VSMC proliferation and BDNF facilitated migration of temporal artery VSMCs in patients with GCA compared to controls. Conclusions: Our results suggest that NTs and NTRs are involved in vascular remodelling of GCA. In GCA-derived temporal artery VSMC, NGF promoted proliferation and BDNF enhanced migration by binding to TrkB and p75NTR receptors. Further experiments are needed on a larger number of VSMC samples to confirm these results.
- 24 November 2014
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 16 (6) , 487
Open AccessNeurotrophins are expressed in giant cell arteritis lesions and may contribute to vascular remodeling
Introduction: Giant cell arteritis (GCA) is characterized by intimal hyperplasia leading to ischaemic manifestations that involve large vessels. Neurotrophins (NTs) and their receptors (NTRs) are protein factors for growth, differentiation and survival of neurons. They are also involved in the migration of vascular smooth muscle cells (VSMCs). Our aim was to investigate whether NTs and NTRs are involved in vascular remodelling of GCA. Methods: We included consecutive patients who underwent a temporal artery biopsy for suspected GCA. We developed an enzymatic digestion method to obtain VSMCs from smooth muscle cells in GCA patients and controls. Neurotrophin protein and gene expression and functional assays were studied from these VSMCs. Neurotrophin expression was also analysed by immunohistochemistry in GCA patients and controls. Results: Whereas temporal arteries of both GCA patients (n = 22) and controls (n = 21) expressed nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), tropomyosin receptor kinase B (TrkB) and sortilin, immunostaining was more intense in GCA patients, especially in the media and intima, while neurotrophin-3 (NT-3) and P75 receptor (P75NTR) were only detected in TA from GCA patients. Expression of TrkB, a BDNF receptor, was higher in GCA patients with ischaemic complications. Serum NGF was significantly higher in GCA patients (n = 28) vs. controls (n = 48), whereas no significant difference was found for BDNF and NT-3. NGF and BDNF enhanced GCA-derived temporal artery VSMC proliferation and BDNF facilitated migration of temporal artery VSMCs in patients with GCA compared to controls. Conclusions: Our results suggest that NTs and NTRs are involved in vascular remodelling of GCA. In GCA-derived temporal artery VSMC, NGF promoted proliferation and BDNF enhanced migration by binding to TrkB and p75NTR receptors. Further experiments are needed on a larger number of VSMC samples to confirm these results.
- 1 May 2013
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 34 (5) , 284-286
Corticothérapie prolongée et alimentation
- 1 May 2013
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 34 (5) , 284-286
Corticothérapie prolongée et alimentation
- 1 April 2012
- Published by Elsevier in La Presse Médicale
- Vol. 41 (4) , 370-377
Pharmacologie des glucocorticoïdes
- 1 April 2012
- Published by Elsevier in La Presse Médicale
- Vol. 41 (4) , 370-377
Pharmacologie des glucocorticoïdes
- 24 February 2012
- Published by Elsevier in La Presse Médicale
- Vol. 41 (4) , 368-9
Corticothérapie : une nécessaire mise au point
- 24 February 2012
- Published by Elsevier in La Presse Médicale
- Vol. 41 (4) , 368-9
Corticothérapie : une nécessaire mise au point
- 1 June 2011
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 32, S31-S35
Risques des médicaments anti-inflammatoires et immunosuppresseurs au cours de la grossesse
- 1 June 2011
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 32, S31-S35
Risques des médicaments anti-inflammatoires et immunosuppresseurs au cours de la grossesse
- 30 September 2008
- Vol. 58 (14) , 1585-9
[Self-medication].